Treating resistant hypertension in type 2 diabetes: A role for spironolactone?

British Journal of Diabetes and Vascular Disease

Volumn 6, Issue 2, 2006, Pages 90-92

  Stanley, Adrian G ^a   Swales, Philip ^b   Thurston, Herbert ^b   Williams, Bryan ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; INSULIN; METFORMIN; SPIRONOLACTONE;

ADULT; ANKLE EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMORBIDITY; DIABETIC HYPERTENSION; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; GYNECOMASTIA; HUMAN; HYPERKALEMIA; INSULIN TREATMENT; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 33646566845     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514060060020701     Document Type: Article

References (12)

1. Anon. Spironolactone: No longer for hypertension. Drug Ther Bull 1988;26:88.
2. Johnston LC, Grieble HG. Treatment of arterial hypertensive disease with diuretics. V. Spironolactone, an aldosterone antagonist. Arch Intern Med 1967;119:225-31.
3. Clement DL. Effect of spironolactone on systemic blood pressure, limb blood flow and response to sympathetic stimulation in hypertensive patients. Eur J Clin Pharmacol 1992;21:263-7.
4. Henry M, Wehrlen M, Pelletier, Capron MH. Spironolactone versus nifedipine in essential hypertension. Am J Cardiol 1990;65:36K-38K.
5. Schohn DC, Spiesser R, Wehrlen M, Pelletier, Capron MH. Aldactazine/ captopril combination, safe and effective in mild to moderate systemic hypertension: report on a multicenter study of 967 patients. Am J Cardiol 1990;65:4K-6K.
6. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.
7. Ouzan J, Pérault C, Lincoff M, Carré E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002;15:333-9.
8. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12A-16A.
9. Falch DK, Schreiner A. The Effect of Spironolactone on Lipid, Glucose and Uric Acid Levels in Blood during Long-Term Administration to Hypertensives. Acta Med Scand 1983;213:27-30.
10. Juurlink DN, Mamdani MM, Lee DS et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51.
11. Winer BM, Lubbe WF, Colton T. Antihypertensive actions of diuretics. Comparative study of an aldosterone antagonist and a thiazide, alone and together. JAMA 1968;204:775-9.
12. Large DM, Carr PH, Laing I, Davies M. Hyperkalaemia in diabetes mellitus - potential hazards of coexisting hyporeninaemic hypoaldosteronism. Postgrad Med J 1984;60:370-3.